{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:25:04Z","timestamp":1792074304862,"version":"4.4.0"},"reference-count":24,"publisher":"Bioscientifica","content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"Parathyroid carcinoma is a rare disease leading to severe hypercalcemia due to hyperparathyroidism. Surgery is the primary treatment option. A more progressive form of the disease is characterized by parathyrotoxicosis, and subsequent hypercalcemia is the most common cause of death. We report a case presenting with severe hypercalcemia due to parathyrotoxicosis from parathyroid carcinoma treated for the first time using the monoclonal antibody denosumab as a rescue therapy and present long-term follow-up data. The 71-year-old patient presented with severe hypercalcemia due to metastatic parathyroid carcinoma. Despite undergoing treatment with bisphosphonates, cinacalcet hydrochloride, and forced diuresis, the patient`s condition deteriorated rapidly due to resistant hypercalcemia. Surgery performed because of spinal metastasis and forced diuresis lowered calcium levels, albeit they remained in the hypercalcemic range and significantly increased when forced diuresis was stopped. Considering a palliative situation to overcome hypercalcemia, we decided to administer denosumab, a monoclonal antibody that binds to the receptor activator of nuclear factor-kappa B ligand. After a single subcutaneous administration of 60\u200amg denosumab, calcium levels normalized within one day. Subsequent denosumab injections led to permanent control of serum calcium for more than 2 years despite rising parathyroid hormone levels and repeated surgeries. Together with recent cases in the literature supporting our observation, we believe that denosumab is relevant for future trials and represents an effective tool to control hypercalcemia in patients with advanced stages of parathyroid cancer.<\/jats:p>\n \n Learning points<\/jats:title>\n \n \n \n Severe hypercalcemia is the most common cause of death in patients with parathyroid carcinoma.<\/jats:p>\n <\/jats:list-item>\n \n The monoclonal antibody denosumab rapidly lowered severely elevated serum calcium levels due to parathyrotoxicosis.<\/jats:p>\n <\/jats:list-item>\n \n Denosumab was effective in the long-term treatment of hypercalcemia despite progression of parathyroid carcinoma.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1530\/edm-15-0082","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T09:03:16Z","timestamp":1447923796000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":8,"title":["Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy"],"prefix":"10.1530","volume":"2015","author":[{"given":"Reiner Jumpertz","family":"von Schwartzenberg","sequence":"first","affiliation":[{"name":"1 Department of Endocrinology and Metabolic Diseases, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Charit\u00e9platz 1, Berlin, 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Elbelt","sequence":"additional","affiliation":[{"name":"1 Department of Endocrinology and Metabolic Diseases, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Charit\u00e9platz 1, Berlin, 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Ventz","sequence":"additional","affiliation":[{"name":"1 Department of Endocrinology and Metabolic Diseases, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Charit\u00e9platz 1, Berlin, 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Mai","sequence":"additional","affiliation":[{"name":"1 Department of Endocrinology and Metabolic Diseases, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Charit\u00e9platz 1, Berlin, 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Kienitz","sequence":"additional","affiliation":[{"name":"1 Department of Endocrinology and Metabolic Diseases, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Charit\u00e9platz 1, Berlin, 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Maurer","sequence":"additional","affiliation":[{"name":"1 Department of Endocrinology and Metabolic Diseases, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Charit\u00e9platz 1, Berlin, 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rose","sequence":"additional","affiliation":[{"name":"2 Division of Rheumatology and Clinical Immunology, Medical Department, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Charit\u00e9platz 1, Berlin, 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens C","family":"R\u00fcckert","sequence":"additional","affiliation":[{"name":"3 Department of General Visceral Vascular and Thoracic Surgery, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Charit\u00e9platz 1, Berlin, 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J","family":"Strasburger","sequence":"additional","affiliation":[{"name":"1 Department of Endocrinology and Metabolic Diseases, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Charit\u00e9platz 1, Berlin, 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Spranger","sequence":"additional","affiliation":[{"name":"1 Department of Endocrinology and Metabolic Diseases, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Charit\u00e9platz 1, Berlin, 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref231","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.4158\/EP14449.CR","article-title":"Denosumab for the treatment of refractory hypercalcemia in metastatic parathyroid carcinoma","volume":"1","year":"2015","journal-title":"AACE Clinical Case Reports"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11864-011-0171-3","article-title":"Parathyroid carcinoma: update and guidelines for management","volume":"13","year":"2012","journal-title":"Current Treatment Options in Oncology"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1200\/JCO.2012.41.7923","article-title":"Denosumab for the treatment of bisphosphonate-refractory hypercalcemia","volume":"30","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1210\/jc.2013-3031","article-title":"Denosumab for management of parathyroid carcinoma-mediated hypercalcemia","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/djt225","article-title":"Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment","volume":"105","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1245\/s10434-010-1003-6","article-title":"Clinical presentation, staging and long-term evolution of parathyroid cancer","volume":"17","year":"2010","journal-title":"Annals of Surgical Oncology"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1245\/s10434-010-1003-6","article-title":"Clinical presentation, staging and long-term evolution of parathyroid cancer","volume":"17","year":"2010","journal-title":"Annals of Surgical Oncology"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1530\/EJE-14-0166","article-title":"Refractory hypercalcaemia secondary to parathyroid carcinoma : response to high - dose denosumab of","author":"GrossmanAB","year":"2014","journal-title":"European Journal Endocrinology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1210\/jc.2011-1571","article-title":"Parathyroid carcinoma: a 43-year outcome and survival analysis","volume":"96","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref211","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1530\/EJE-14-0166","article-title":"Refractory hypercalcaemia secondary to parathyroid carcinoma : response to high - dose denosumab of","author":"GrossmanAB","year":"2014","journal-title":"European Journal Endocrinology"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1200\/JCO.2012.41.7923","article-title":"Denosumab for the treatment of bisphosphonate-refractory hypercalcemia","volume":"30","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.4158\/EP14449.CR","article-title":"Denosumab for the treatment of refractory hypercalcemia in metastatic parathyroid carcinoma","volume":"1","year":"2015","journal-title":"AACE Clinical Case Reports"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/jcem.86.2.7207","article-title":"Clinical review 122: parathyroid carcinoma","volume":"86","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1210\/jc.2013-3031","article-title":"Denosumab for management of parathyroid carcinoma-mediated hypercalcemia","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s00268-010-0722-y","article-title":"Lymph node involvement and surgical approach in parathyroid cancer","volume":"34","year":"2010","journal-title":"World Journal of Surgery"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11864-011-0171-3","article-title":"Parathyroid carcinoma: update and guidelines for management","volume":"13","year":"2012","journal-title":"Current Treatment Options in Oncology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/djt225","article-title":"Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment","volume":"105","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s00268-010-0722-y","article-title":"Lymph node involvement and surgical approach in parathyroid cancer","volume":"34","year":"2010","journal-title":"World Journal of Surgery"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1210\/jc.2011-1571","article-title":"Parathyroid carcinoma: a 43-year outcome and survival analysis","volume":"96","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5694\/mja12.11243","article-title":"Resistant hypercalcaemia in metastatic parathyroid carcinoma","volume":"198","year":"2013","journal-title":"Medical Journal of Australia"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5694\/mja12.11243","article-title":"Resistant hypercalcaemia in metastatic parathyroid carcinoma","volume":"198","year":"2013","journal-title":"Medical Journal of Australia"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/jcem.86.2.7207","article-title":"Clinical review 122: parathyroid carcinoma","volume":"86","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2015\/1\/EDM15-0082.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2015\/1\/EDM15-0082.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:10Z","timestamp":1784555170000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,1]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1530\/edm-15-0082","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,1]]}}}